Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders ...

The protein STAT3 is often overactive in these cells. Attempts to inhibit its activity therapeutically have—so far—not been ...

New research identifies the liver protein PTPRD as a key regulator of metabolic liver disease. Reduced levels of PTPRD disrupt glucose and lipid metabolism, promote liver fat accumulation, and impair ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal ...